PP
BMRN icon

Paloma Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paloma Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,800
Closed -$237K – 1305
2019
Q4 		$237K Buy
+2,800
New +$211K ﹤0.01% 1892

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Paloma Partners's BMRN Position: Q4 2024 in Review

Paloma Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 3,402 shares — an estimated $239K sold.

Paloma Partners first reported a position in BMRN in Q2 2014 and held it in 36 quarters. The position peaked at $14M in Q2 2015. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Paloma Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 3,402 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $239K.
  • Paloma Partners first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 36 quarters.
  • Paloma Partners's BioMarin Pharmaceuticals position peaked at $14M in Q2 2015.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.